Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RCEL Stock Summary
Top 10 Correlated ETFs
RCEL
In the News

AVITA Medical to Present at the Cantor Global Healthcare Conference
VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023, at 11:05 a.m. Eastern Time.

AVITA Medical to Participate in Upcoming Investor Conferences
VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that its management team will participate in the following upcoming investor conferences:

AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Brooks O'Neil - Lake Street Capital Markets Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Ross Osborne - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. Second Quarter 2023 Earnings Call.

AVITA Medical's 'Better Mousetrap' Rapidly Gaining Traction In Skin Repair
AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo greatly expand addressable market. Expanded sales force positioned to capitalize.

Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?
Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Shares of Avita Medical Are Soaring Thursday
Avita specializes in devices and therapies to restore skin growth. The FDA's nod means that the company's Recell system can expand beyond applications for burn patients.

AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System
AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects.

AVITA Medical, Inc. (RCEL) Q1 2023 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Phillip Dantoin - Piper Sandler Ryan Zimmerman - BTIG Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2023 Earnings Conference Call.

Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

AVITA Medical to Announce First Quarter 2023 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, April 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 11, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 12, 2023, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.
RCEL Financial details
RCEL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-06-30 | 2020-06-30 | 2021-06-30 | 2021-06-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.13 | 0.34 | 0.7 | 1.29 | 1.38 | |
Net income per share | -1.3 | -1.53 | -2.07 | -1.17 | -1.07 | |
Operating cash flow per share | -1.29 | -1.2 | -1.12 | -1.14 | -0.76 | |
Free cash flow per share | -1.33 | -1.25 | -1.16 | -1.19 | -0.78 | |
Cash per share | 1.17 | 1.26 | 3.63 | 4.88 | 3.17 | |
Book value per share | 1.5 | 1.3 | 3.57 | 5.1 | 3.39 | |
Tangible book value per share | 1.5 | 1.28 | 3.55 | 5.08 | 3.37 | |
Share holders equity per share | 1.5 | 1.3 | 3.57 | 5.1 | 3.39 | |
Interest debt per share | 0.01 | 0 | 0.1 | 0.04 | 0.04 | |
Market cap | 68.01M | 709.12M | 416.37M | 465.28M | 165M | |
Enterprise value | 57.22M | 688.86M | 344.65M | 355.41M | 147.76M | |
P/E ratio | -5.62 | -28.8 | -9.91 | -17.5 | -6.19 | |
Price to sales ratio | 56.04 | 131.41 | 29.19 | 15.92 | 4.79 | |
POCF ratio | -5.66 | -36.84 | -18.3 | -17.96 | -8.64 | |
PFCF ratio | -5.49 | -35.29 | -17.65 | -17.18 | -8.41 | |
P/B Ratio | 4.86 | 33.99 | 5.75 | 4.02 | 1.95 | |
PTB ratio | 4.86 | 33.99 | 5.75 | 4.02 | 1.95 | |
EV to sales | 47.15 | 127.65 | 24.16 | 12.16 | 4.29 | |
Enterprise value over EBITDA | -4.36 | -27.86 | -8.3 | -13.4 | -5.67 | |
EV to operating cash flow | -4.76 | -35.79 | -15.15 | -13.72 | -7.74 | |
EV to free cash flow | -4.62 | -34.28 | -14.61 | -13.13 | -7.53 | |
Earnings yield | -0.18 | -0.03 | -0.1 | -0.06 | -0.16 | |
Free cash flow yield | -0.18 | -0.03 | -0.06 | -0.06 | -0.12 | |
Debt to equity | 0.01 | 0 | 0.03 | 0.01 | 0.01 | |
Debt to assets | 0.01 | 0 | 0.02 | 0.01 | 0.01 | |
Net debt to EBITDA | 0.82 | 0.82 | 1.73 | 4.14 | 0.66 | |
Current ratio | 5.75 | 5.5 | 10.17 | 16.42 | 8.18 | |
Interest coverage | -672.47 | -934.69 | -1.29K | -1.21K | -1.72K | |
Income quality | 0.99 | 0.78 | 0.54 | 0.97 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 6.63 | 2.35 | 2.43 | 0.77 | 0.68 | |
Research and developement to revenue | 5.24 | 1.86 | 0.59 | 0.51 | 0.4 | |
Intangibles to total assets | 0 | 0.01 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0.04 | 0.04 | 0.05 | 0.03 | |
Capex to revenue | -0.3 | -0.16 | -0.06 | -0.04 | -0.02 | |
Capex to depreciation | -3.47 | -3.2 | -1.82 | -1.64 | -0.92 | |
Stock based compensation to revenue | 0 | 0.36 | 1.16 | 0.19 | 0.2 | |
Graham number | 6.62 | 6.69 | 12.9 | 11.6 | 9.02 | |
ROIC | -0.85 | -1.17 | -0.56 | -0.23 | -0.32 | |
Return on tangible assets | -0.72 | -0.97 | -0.51 | -0.21 | -0.27 | |
Graham Net | 1.22 | 1.08 | 3.25 | 4.73 | 2.82 | |
Working capital | 13.54M | 19.82M | 70.68M | 113.94M | 76.77M | |
Tangible asset value | 13.98M | 20.64M | 72.04M | 115.18M | 84.28M | |
Net current asset value | 13.44M | 19.35M | 68.33M | 111.48M | 73.93M | |
Invested capital | 0.01 | 0 | 0.03 | 0.01 | 0.01 | |
Average receivables | 2.81M | 3.05M | 2.26M | 4.92M | 6.18M | |
Average payables | 2.19M | 3.25M | 4.14M | 3.73M | 3.06M | |
Average inventory | 823.16K | 794.93K | 932.9K | 1.39M | 1.89M | |
Days sales outstanding | 1.21K | 141.17 | 62.24 | 92.44 | 52.6 | |
Days payables outstanding | 1.81K | 1.21K | 531.97 | 191.43 | 181.38 | |
Days of inventory on hand | 598.43 | 227.4 | 138.12 | 101.05 | 128.39 | |
Receivables turnover | 0.3 | 2.59 | 5.86 | 3.95 | 6.94 | |
Payables turnover | 0.2 | 0.3 | 0.69 | 1.91 | 2.01 | |
Inventory turnover | 0.61 | 1.61 | 2.64 | 3.61 | 2.84 | |
ROE | -0.87 | -1.18 | -0.58 | -0.23 | -0.31 | |
Capex per share | -0.04 | -0.05 | -0.04 | -0.05 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.33 | 0.36 | 0.42 | 0.42 | 0.47 | |
Net income per share | -0.25 | -0.22 | -0.24 | -0.37 | -0.41 | |
Operating cash flow per share | -0.14 | -0.11 | -0.15 | -0.36 | -0.36 | |
Free cash flow per share | -0.15 | -0.12 | -0.16 | -0.37 | -0.37 | |
Cash per share | 3.38 | 3.37 | 3.5 | 2.91 | 2.62 | |
Book value per share | 3.71 | 3.52 | 3.74 | 3.08 | 2.72 | |
Tangible book value per share | 3.69 | 3.5 | 3.72 | 3.06 | 2.7 | |
Share holders equity per share | 3.71 | 3.52 | 3.74 | 3.08 | 2.72 | |
Interest debt per share | 0.02 | 0.04 | 0.04 | 0.07 | 0.07 | |
Market cap | 118.61M | 131.79M | 149.65M | 352.07M | 429.33M | |
Enterprise value | 84.41M | 109.29M | 132.4M | 325.9M | 392.89M | |
P/E ratio | -4.74 | -5.9 | -6.99 | -9.55 | -10.34 | |
Price to sales ratio | 14.23 | 14.49 | 15.83 | 33.37 | 36.53 | |
POCF ratio | -33.82 | -47.46 | -43.55 | -38.8 | -47.17 | |
PFCF ratio | -31.71 | -45.41 | -42.44 | -37.56 | -45.65 | |
P/B Ratio | 1.28 | 1.5 | 1.77 | 4.54 | 6.25 | |
PTB ratio | 1.28 | 1.5 | 1.77 | 4.54 | 6.25 | |
EV to sales | 10.13 | 12.02 | 14 | 30.89 | 33.43 | |
Enterprise value over EBITDA | -13.8 | -20.09 | -25.5 | -36.01 | -37.91 | |
EV to operating cash flow | -24.07 | -39.36 | -38.53 | -35.92 | -43.17 | |
EV to free cash flow | -22.56 | -37.66 | -37.55 | -34.77 | -41.77 | |
Earnings yield | -0.05 | -0.04 | -0.04 | -0.03 | -0.02 | |
Free cash flow yield | -0.03 | -0.02 | -0.02 | -0.03 | -0.02 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
Net debt to EBITDA | 5.59 | 4.13 | 3.32 | 2.89 | 3.52 | |
Current ratio | 11.64 | 9.64 | 8.18 | 7.21 | 5.61 | |
Interest coverage | -1.59K | -958 | -984.67 | -2.48K | -1.6K | |
Income quality | 0.56 | 0.5 | 0.64 | 0.98 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.66 | 0.55 | 0.56 | 0.79 | 0.52 | |
Research and developement to revenue | 0.37 | 0.42 | 0.36 | 0.43 | 0.43 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.01 | |
Capex to operating cash flow | 0.07 | 0.05 | 0.03 | 0.03 | 0.03 | |
Capex to revenue | -0.03 | -0.01 | -0.01 | -0.03 | -0.03 | |
Capex to depreciation | -1.71 | -0.91 | -0.69 | -2.23 | -2.08 | |
Stock based compensation to revenue | 0.17 | 0.16 | 0.13 | 0.25 | 0.1 | |
Graham number | 4.57 | 4.21 | 4.46 | 5.03 | 5.02 | |
ROIC | -0.07 | -0.06 | -0.07 | -0.12 | -0.16 | |
Return on tangible assets | -0.06 | -0.06 | -0.05 | -0.1 | -0.12 | |
Graham Net | 3.15 | 3.06 | 3.11 | 2.53 | 2.16 | |
Working capital | 83.92M | 82.21M | 76.77M | 71.28M | 63.69M | |
Tangible asset value | 92.13M | 87.54M | 84.28M | 77.1M | 68.19M | |
Net current asset value | 81.7M | 79.77M | 73.93M | 67.7M | 59.81M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
Average receivables | 4.28M | 4.45M | 4.73M | 5.07M | 5.69M | |
Average payables | 2.45M | 3.05M | 3.3M | 3.38M | 3.79M | |
Average inventory | 1.91M | 1.99M | 2.04M | 2.47M | 2.93M | |
Days sales outstanding | 47.37 | 44.62 | 47.21 | 44.2 | 47.45 | |
Days payables outstanding | 162.01 | 211.65 | 200.58 | 202.57 | 156.68 | |
Days of inventory on hand | 131.3 | 115.29 | 141.98 | 151.76 | 124.87 | |
Receivables turnover | 1.9 | 2.02 | 1.91 | 2.04 | 1.9 | |
Payables turnover | 0.56 | 0.43 | 0.45 | 0.44 | 0.57 | |
Inventory turnover | 0.69 | 0.78 | 0.63 | 0.59 | 0.72 | |
ROE | -0.07 | -0.06 | -0.06 | -0.12 | -0.15 | |
Capex per share | -0.01 | 0 | 0 | -0.01 | -0.01 |
RCEL Frequently Asked Questions
What is AVITA Medical, Inc. stock symbol ?
AVITA Medical, Inc. is a US stock , located in Valencia of Ca and trading under the symbol RCEL
What is AVITA Medical, Inc. stock quote today ?
AVITA Medical, Inc. stock price is $14.63 today.
Is AVITA Medical, Inc. stock public?
Yes, AVITA Medical, Inc. is a publicly traded company.